These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 32223973)

  • 21. Plasma levels of soluble amyloid precursor protein β in symptomatic Alzheimer's disease.
    Alexopoulos P; Gleixner LS; Werle L; Buhl F; Thierjung N; Giourou E; Kagerbauer SM; Gourzis P; Kübler H; Grimmer T; Yakushev I; Martin J; Kurz A; Perneczky R
    Eur Arch Psychiatry Clin Neurosci; 2018 Aug; 268(5):519-524. PubMed ID: 28602012
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alteration of thiol disulfide homeostasis and ischemia-modified albumin levels as indicators of oxidative status in patients with silicosis.
    Karataş M; Büyükşekerci M; Gündüzöz M; Özakıncı G; Öziş TN; Gök G; Neşelioğlu S; Erel Ö
    Toxicol Ind Health; 2021 Jan; 37(1):38-46. PubMed ID: 33305688
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potential fluid biomarkers for pathological brain changes in Alzheimer's disease: Implication for the screening of cognitive frailty.
    Ruan Q; D'Onofrio G; Sancarlo D; Greco A; Yu Z
    Mol Med Rep; 2016 Oct; 14(4):3184-98. PubMed ID: 27511317
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased Plasma Beta-Secretase 1 May Predict Conversion to Alzheimer's Disease Dementia in Individuals With Mild Cognitive Impairment.
    Shen Y; Wang H; Sun Q; Yao H; Keegan AP; Mullan M; Wilson J; Lista S; Leyhe T; Laske C; Rujescu D; Levey A; Wallin A; Blennow K; Li R; Hampel H
    Biol Psychiatry; 2018 Mar; 83(5):447-455. PubMed ID: 28359566
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Systemic inflammatory markers in age-associated cognitive impairment and Alzheimer's disease].
    Kliushnik TP; Androsova LV; Mikhaylova NM; Kolykhalov IV; Zozulya SA; Dupin AM
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(7):74-79. PubMed ID: 28805765
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel Blood Biomarkers that Correlate with Cognitive Performance and Hippocampal Volumetry: Potential for Early Diagnosis of Alzheimer's Disease.
    Hudd F; Shiel A; Harris M; Bowdler P; McCann B; Tsivos D; Wearn A; Knight M; Kauppinen R; Coulthard E; White P; Conway ME
    J Alzheimers Dis; 2019; 67(3):931-947. PubMed ID: 30689581
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thiol-disulfide homeostasis and ischemia-modified albumin levels as indicators of oxidative stress in welders' lung disease.
    Karataş M; Öziş TN; Büyükşekerci M; Gündüzöz M; Özakıncı OG; Gök G; Neşelioğlu S; Erel Ö
    Hum Exp Toxicol; 2019 Nov; 38(11):1227-1234. PubMed ID: 31451031
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum Non-Ceruloplasmin Non-Albumin Copper Elevation in Mild Cognitive Impairment and Dementia due to Alzheimer's Disease: A Case Control Study.
    Rozzini L; Lanfranchi F; Pilotto A; Catalani S; Gilberti ME; Paganelli M; Apostoli P; Padovani A
    J Alzheimers Dis; 2018; 61(3):907-912. PubMed ID: 29332043
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Novel Peptidome Technology for the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease by Selected Reaction Monitoring.
    Fukui Y; Tadokoro K; Hamada M; Asada K; Lee LJ; Tachiki H; Morihara R; Abe K; Yamashita T
    J Alzheimers Dis; 2024; 100(1):219-228. PubMed ID: 38848173
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oxidative signature of cerebrospinal fluid from mild cognitive impairment and Alzheimer disease patients.
    Di Domenico F; Pupo G; Giraldo E; Badìa MC; Monllor P; Lloret A; Schininà ME; Giorgi A; Cini C; Tramutola A; Butterfield DA; Viña J; Perluigi M
    Free Radic Biol Med; 2016 Feb; 91():1-9. PubMed ID: 26675344
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HO-1/BVR-a system analysis in plasma from probable Alzheimer's disease and mild cognitive impairment subjects: a potential biochemical marker for the prediction of the disease.
    Di Domenico F; Barone E; Mancuso C; Perluigi M; Cocciolo A; Mecocci P; Butterfield DA; Coccia R
    J Alzheimers Dis; 2012; 32(2):277-89. PubMed ID: 22776971
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of β2-microglobulin serum level between Alzheimer's patients, cognitive healthy and mild cognitive impaired individuals.
    Dominici R; Finazzi D; Polito L; Oldoni E; Bugari G; Montanelli A; Scarpini E; Galimberti D; Guaita A
    Biomarkers; 2018 Sep; 23(6):603-608. PubMed ID: 29741401
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oxidative Stress Assessment in Alzheimer's Disease: A Clinic Setting Study.
    Vergallo A; Giampietri L; Baldacci F; Volpi L; Chico L; Pagni C; Giorgi FS; Ceravolo R; Tognoni G; Siciliano G; Bonuccelli U
    Am J Alzheimers Dis Other Demen; 2018 Feb; 33(1):35-41. PubMed ID: 28931301
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The new 2011 recommendations of the National Institute on Aging and the Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinal stages, mild cognitive impairment, and dementia].
    Croisile B; Auriacombe S; Etcharry-Bouyx F; Vercelletto M; ;
    Rev Neurol (Paris); 2012 Jun; 168(6-7):471-82. PubMed ID: 22579080
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potential neuroimaging biomarkers of pathologic brain changes in Mild Cognitive Impairment and Alzheimer's disease: a systematic review.
    Ruan Q; D'Onofrio G; Sancarlo D; Bao Z; Greco A; Yu Z
    BMC Geriatr; 2016 May; 16():104. PubMed ID: 27184250
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of dynamic/thiol disulphide balance and ischaemia modified albumin in children with trauma.
    Öztorun Cİ; Doruk H; Güney D; Köse ÜNİ; Örnek Demir T; Çayhan VS; Demir S; Ertürk A; Güngör A; Kara Uzun A; Nural C; Neşelioğlu S; Azılı MN; Şenel E
    Int J Clin Pract; 2021 Nov; 75(11):e14713. PubMed ID: 34374172
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oxidative stress parameters in patients with ascending aortic dilatation.
    Erdoğan M; Polat M; Çelik MC; Öztürk S; Baştuğ S; Özbebek YE; Neşelioğlu S; Akçay M
    Turk J Med Sci; 2020 Aug; 50(5):1323-1329. PubMed ID: 32421280
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.
    Gangishetti U; Christina Howell J; Perrin RJ; Louneva N; Watts KD; Kollhoff A; Grossman M; Wolk DA; Shaw LM; Morris JC; Trojanowski JQ; Fagan AM; Arnold SE; Hu WT
    Alzheimers Res Ther; 2018 Sep; 10(1):98. PubMed ID: 30253800
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type.
    Popp J; Wolfsgruber S; Heuser I; Peters O; Hüll M; Schröder J; Möller HJ; Lewczuk P; Schneider A; Jahn H; Luckhaus C; Perneczky R; Frölich L; Wagner M; Maier W; Wiltfang J; Kornhuber J; Jessen F
    Neurobiol Aging; 2015 Feb; 36(2):601-7. PubMed ID: 25435336
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potential oxidative stress biomarkers of mild cognitive impairment due to Alzheimer disease.
    García-Blanco A; Baquero M; Vento M; Gil E; Bataller L; Cháfer-Pericás C
    J Neurol Sci; 2017 Feb; 373():295-302. PubMed ID: 28131209
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.